Evoke Pharma Inc. (NASDAQ:EVOK) shares saw unusually-strong trading volume on Monday . Approximately 7,714,380 shares traded hands during trading, an increase of 1,425% from the previous session’s volume of 505,870 shares.The stock last traded at $3.11 and had previously closed at $10.73.

A number of equities research analysts recently commented on EVOK shares. Brean Capital restated a “buy” rating on shares of Evoke Pharma in a report on Wednesday, April 6th. Zacks Investment Research upgraded shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a report on Tuesday, May 3rd. Rodman & Renshaw restated a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. Finally, FBR & Co restated a “buy” rating on shares of Evoke Pharma in a report on Saturday, May 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Evoke Pharma presently has a consensus rating of “Hold” and an average target price of $14.34.

The company’s 50-day moving average price is $6.71 and its 200 day moving average price is $4.83. The stock’s market capitalization is $20.92 million.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. On average, analysts expect that Evoke Pharma Inc. will post ($1.37) earnings per share for the current year.

In related news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of the stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total value of $25,831.65. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.